The role of metastasectomy in renal cell carcinoma in the era of targeted therapy

Current Urology Reports

Volumn 14, Issue 1, 2013, Pages 19-25

  Ljungberg, Börje ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Metastasectomy; Metastases; Renal cell carcinoma; Survival; Targeted agents

Indexed keywords

SUNITINIB;

ADRENAL METASTASIS; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE INTERVAL; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LUNG RESECTION; METASTASIS; METASTASIS RESECTION; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; ORTHOPEDIC SURGERY; OVERALL SURVIVAL; PANCREAS METASTASIS; PANCREAS SURGERY; SEX DIFFERENCE; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; METASTASECTOMY; NEOADJUVANT THERAPY; NEPHRECTOMY; PROGNOSIS; TREATMENT OUTCOME;

EID: 84872413264     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0293-6     Document Type: Article

References (42)

1. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003;4(5):385-90.
2. Swanson DA. Surgery for metastases of renal cell carcinoma. Scand J Surg. 2004;93:150-5.
3. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol. 2000;34:246-51.
4. •• Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011;108:1556-63. In this Cochrane systematic review, it was concluded that agents targeting VEGF and mTOR pathways improve PFS in both first-line and second-line settings. The authors found that the treatments rarely yield complete responses and thus are not curative. However, no placebo-controlled trial has reported a health-related quality of life benefit.
5. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071-6.
6. Kwan KG, Kapoor A. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. Curr Opin Support Palliat Care. 2009;3:157-65.
7. •• Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. EAU guidelines on renal cell carcinoma: the 2010 update European Association of Urology Guideline Group. Eur Urol. 2010;58:398-406. Evidence-based guidelines with recommendations for the treatment of an individual patient with renal cell carcinoma, according to a current standardized general approach.
8. Russo P, Synder M, Vickers A, Kondagunta V, Motzer R. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. Sci World J. 2007;7:768-78.
9. Russo P. Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol. 2010;28(3):295-301.
10. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol. 1999;35(3):197-203.
11. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16:2261-6.
12. Kierney PC, van Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol. 1994;1:345-52.
13. • Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011, 117(13), 2873-82. Out of 887 patients, 125 were treated with complete surgical resection of all metastases, achieving a significant prolongation of cancer-specific survival. Especially patients with lung-only metastases had a 74 % 5-year survival. Survival advantage was suggested for multiple metastases after complete metastasectomy. It was concluded that complete metastasectomy should be considered when technically feasible in appropriate surgical candidates.
14. Swanson DA. Surgery for metastases of renal cell carcinoma. Scand J Surg. 2004;93(2):150-5.
15. Kwak C, Park YH, Jeong CW, Lee SE, Ku JH. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment. Urol Int. 2007;79:145-51.
16. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 2002;74:1653-7.
17. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005;48:77-81.
18. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007;89:1794-801.
19. Kollender Y, Bickels J, Price WM, Kellar KL, Chen J, Merimsky O, Meller I, Malawer MM. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol. 2000;164:1505-8.
20. Szendroi A, Dinya E, Kardos M, Szász AM, Németh Z, Ats K, Kiss J, Antal I, Romics I, Szendroi M. Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases. Pathol Oncol Res. 2010;16:29-38.
21. • Ruys AT, Tanis PJ, Iris ND, van Duijvendijk P, Verhoef C, Porte RJ, van Gulik TM. Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol. 2011;18:1932-8. In a nationwide study, a favorable 5-year survival rate of 43 % was observed after surgery of RCC liver metastases. They had no operative mortality, The study indicates that selected patients with RCCLM can benefit from surgical treatment of RCC liver metastases.
22. Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, Stief CG, Jauch KW, Bruns CJ. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol. 2010;28:543-7.
23. Ballarin R, Spaggiari M, Cautero N, De Ruvo N, Montalti R, Longo C, Pecchi A, Giacobazzi P, De Marco G, D'Amico G, Gerunda GE, Di Benedetto F. Pancreatic metastases from renal cell carcinoma: the state of the art. World J Gastroenterol. 2011;17:4747-56.
24. Sohn TA, Yeo CJ, Cameron JL, Nakeeb A, Lillemoe KD. Renal cell carcinoma metastatic to the pancreas: results of surgical management. J Gastrointest Surg. 2001;5(4):346-51.
25. Ghavamian R, Klein KA, Stephens DH, Welch TJ, LeRoy AJ, Richardson RL, Burch PA, Zincke H. Renal cell carcinoma metastatic to the pancreas: clinical and radiological features. Mayo Clin Proc. 2000;75(6):581-5.
26. Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 2009;10:287-93.
27. Alamdari FI, Ljungberg B. Adrenal metastasis in renal cell carcinoma: a recommendation for adjustment of the TNM staging system. Scand J Urol Nephrol. 2005;39(4):277-82.
28. Muth A, Persson F, Jansson S, Johanson V, Ahlman H, Wängberg B. Prognostic factors for survival after surgery for adrenal metastasis. Eur J Surg Oncol. 2010;36(7):699-704.
29. Antonelli A, Cozzoli A, Simeone C, et al. Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients. BJU Int. 2006;97:505-8.
30. Kim SH, Brennan MF, Russo P, Burt ME, Coit DG. The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer. 1998;82:389-94.
31. Nieder C, Spanne O, Nordøy T, Dalhaug A. Treatment of brain metastases from renal cell cancer. Urol Oncol. 2011;29:405-10.
32. Muacevic A, Kreth FW, Horstmann GA, Schmid-Elsaesser R, Wowra B, Steiger HJ, Reulen HJ. Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg. 1999;91:35-43.
33. Hassaneen W, Suki D, Salaskar AL, Wildrick DM, Lang FF, Fuller GN, Sawaya R. Surgical management of lateral-ventricle metastases: report of 29 cases in a single-institution experience. J Neurosurg. 2010;112:1046-55.
34. Shuto T, Matsunaga S, Suenaga J, Inomori S, Fujino H. Treatment strategy for metastatic brain tumors from renal cell carcinoma: selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema. J Neurooncol. 2010;98:169-75.
35. Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg. 2012;116(5):978-83.
36. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008;180:873-8.
37. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005;174:1759-63.
38. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006;24:3101-6.
39. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
40. • Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011;185:439-44. In this study, metastasectomy after targeted therapy was evaluated based on results from three different centres. The authors conclude that in a cohort of select patients (22) with a limited tumor burden after treatment with targeted agents, consolidative metastasectomy is feasible giving a long-term tumor-free status.
41. • Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010;28:1502-150. The authors show a reduction in tumor size with near 10 % and radiographic evidence of loss of intratumoral enhancement after one course of sorafenib therapy. Of the 28 patients evaluable for response, none progressed on therapy. All patients were able to proceed to surgery.
42. • Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC. Surgical resection of renal cell carcinoma after targeted therapy. J Urol. 2009;182:881-6. The study reports on the feasibility to perform surgical resection of possibly unresectable renal cell carcinoma after targeted therapy. In most patients there with a low morbidity, but significant complications can occur.